1
|
Winter K, Pfeil JM, Engmann H, Aisenbrey S, Lorenz B, Hufendiek K, Breuss H, Khattab M, Süsskind D, Kakkassery V, Lagrèze WA, Barth T, Liegl R, Bründer MC, Skevas C, Goldammer I, Glitz B, Michalewicz E, Krohne TU, Bartmann IR, Stahl A. Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. Acta Ophthalmol 2024; 102:e314-e321. [PMID: 37725047 DOI: 10.1111/aos.15753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 07/04/2023] [Accepted: 08/29/2023] [Indexed: 09/21/2023]
Abstract
PURPOSE The German Retina.net ROP registry and its Europe-wide successor, the EU-ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries. METHODS Exemplary datasets from the two databases over a 1-year period each (German Retina.net ROP Registry, 2011, 22 infants; EU-ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments. RESULTS The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU-ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10-12 clock hours in 29% of cases, 2021: 4-6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti-VEGF therapy in 2021 (86.1%). Within the anti-VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021. CONCLUSION Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti-VEGF, and within the anti-VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.
Collapse
Affiliation(s)
- K Winter
- Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany
| | - J M Pfeil
- Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany
| | - H Engmann
- Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany
| | - S Aisenbrey
- Department of Ophthalmology, Vivantes Klinikum Neukoelln, Berlin, Germany
| | - B Lorenz
- Department of Ophthalmology, University Medicine Giessen and Marburg GmbH Giessen Campus, Giessen, Germany
| | - K Hufendiek
- University Eye Hospital, Hannover Medical School, Hannover, Germany
| | - H Breuss
- Department of Ophthalmology, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - M Khattab
- Department of Ophthalmology, University Medical Center Goettingen, Goettingen, Germany
| | - D Süsskind
- University Eye Hospital, Eberhard Karls University of Tuebingen, Tuebingen, Germany
| | - V Kakkassery
- Department of Ophthalmology, University of Luebeck, Luebeck, Germany
| | - W A Lagrèze
- Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - T Barth
- Department of Ophthalmology, University of Regensburg, Regensburg, Germany
| | - R Liegl
- Department of Ophthalmology, University Medicine Bonn, Bonn, Germany
| | - M C Bründer
- Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany
| | - C Skevas
- Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I Goldammer
- Department of Ophthalmology, Klinikum Chemnitz gGmbH, Chemnitz, Germany
| | - B Glitz
- Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany
| | - E Michalewicz
- Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
| | - T U Krohne
- Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - I R Bartmann
- Department of Ophthalmology, Klinikum Fulda, Faculty of Medicine/Campus Fulda, University of Marburg, Fulda, Germany
| | - A Stahl
- Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany
| |
Collapse
|
2
|
Khattab M, Assaad-Khalil S, Elibrashy I, Khalifa A, Amara F, Elgayyar H, Elkafrawy N, George S, Ghanem Y, Hafez S, Shereiba N. Control and treatment of type 2 diabetes in private patients in the Egyptian "DIACONTROL study". Eur Rev Med Pharmacol Sci 2023; 27:11421-11432. [PMID: 38095390 DOI: 10.26355/eurrev_202312_34581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]
Abstract
OBJECTIVE This study aims to identify the characteristics of Egyptian patients suffering from type 2 diabetes mellitus (T2DM), determine disease control rates, and gain insights into clinical treatments. PATIENTS AND METHODS A total of 2,516 patients with T2DM were recruited from 244 private clinics across Egypt in a one-month period from May to June 2017. Data collected from patients included glycemic control parameters of glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose. Additional information gathered included patients' weight, age, level of physical activity, smoking habits, presence of comorbidities, type of treatment received for type 2 diabetes, number and severity of hypoglycemic events, as well as treatment modification by the physician in the last visit. The type of statistics used for the analysis is descriptive statistics and regression model. RESULTS Only 18.4% of participating patients achieved the target level of glycosylated hemoglobin of 7% or below. The mean age of these patients was 54±11.2 years, and the mean duration since the first diagnosis was 6.6±6.4 years. A total of 33.4% of all patients had no known comorbidity, while the rest had one or more known and treated comorbidities. A total of 76% of patients received sulfonylurea either as monotherapy or in combination with other treatments. In addition, no treatment modifications or adjustments were provided for 32% of the study participants who did not reach their glycemic control target. CONCLUSIONS In Egypt, there is a low rate of glycemic control among private patients and a high prevalence of comorbid conditions. This is likely to cause a significant health burden to people with T2DM, the healthcare system, and the economy due to a loss in productivity. This study presented an argument for better-managed measures to improve glycemic control in the population, such as patient education to increase patient awareness and adherence to treatment protocols as well as improved adherence to guidelines by clinicians.
Collapse
Affiliation(s)
- M Khattab
- Faculty of Medicine, Cairo University, Cairo, Egypt.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Benlhachemi S, Abouqal R, Coleman N, Murray MJ, Khattab M, El fahime E. Circulating microRNA profiles in Wilms tumour (WT): A systematic review and meta-analysis of diagnostic test accuracy. Noncoding RNA Res 2023; 8:413-425. [PMID: 37305178 PMCID: PMC10247954 DOI: 10.1016/j.ncrna.2023.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/24/2023] [Accepted: 05/25/2023] [Indexed: 06/13/2023] Open
Abstract
Background Wilms tumour (WT) is caused by aberrant embryonic kidney development and associated with dysregulated expression of short, non-protein-coding RNAs termed microRNAs (miRNAs). At present, there is no reliable circulating biomarker of WT, and this remains an urgent unmet clinical need. Such biomarkers may assist diagnosis, subtyping/prognostication, and disease-monitoring. Here, we established the list of dysregulated circulating miRNAs in WT from the existing published literature. Methods Regardless of publication date, PubMed, Scopus, Web-of-Science, and Wiley online library databases were searched for English/French studies on WT circulating miRNAs. The PRISMA-compliant search was registered in PROSPERO. The QUADAS tool measured retained article quality. The meta-analysis assessed the sensitivity and specificity of miRNAs for WT diagnosis. Results Qualitative analysis included 280 samples (172 WT patients; 108 healthy controls) from five of 450 published articles. The study uncovered 301 dysregulated miRNAs (144 up-regulated, 143 down-regulated, 14 conflicting). The pooled sensitivity, specificity, and AUC of the 49 significantly dysregulated microRNAs from two studies was 0.67 [0.62; 0.73], 0.95 [0.92; 0.96] and 0.77 [0.73; 0.81] respectively, indicating a stronger diagnostic potential for WT. Conclusions Circulating miRNAs show promise for WT diagnosis and prognosis. More research is needed to confirm these findings and determine associations with tumour stage/subtype. Prospero registration number CRD42022301597.
Collapse
Affiliation(s)
- Sara Benlhachemi
- Laboratory of Genomics and Molecular Epidemiology of Genetic Diseases (GE2MG). Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
- Molecular Biology and Functional Genomics Platform, National Center for Scientific and Technical Research, Rabat, Morocco
| | - Redouane Abouqal
- Biostatistics Laboratory, Clinical Epidemiology Research. Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco
| | - Nicholas Coleman
- Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK
- Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - Matthew Jonathan Murray
- Department of Pathology, University of Cambridge, Cambridge, CB2 1QP, UK
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
| | - Mohammed Khattab
- Department of Paediatric Haematology and Oncology, Abulcasis International University of Health Sciences, Rabat, Morocco
| | - Elmostafa El fahime
- Molecular Biology and Functional Genomics Platform, National Center for Scientific and Technical Research, Rabat, Morocco
| |
Collapse
|
4
|
Viprakasit V, Hamdy MM, Hassab HMA, Sherief LM, Al-Bagshi M, Khattab M, Chuncharunee S, Dung PC, Küpesiz A, Shekhawat A, Sonawane Y, Perez LT, Slader C, Taher AT. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia. Ann Hematol 2023:10.1007/s00277-023-05240-3. [PMID: 37227493 DOI: 10.1007/s00277-023-05240-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 04/17/2023] [Indexed: 05/26/2023]
Abstract
Iron chelation therapy (ICT) is the mainstay of treatment in patients with thalassemia requiring blood transfusions. This phase 2 JUPITER study evaluated patient preference between film-coated tablet (FCT) and dispersible tablet (DT) in transfusion-dependent thalassemia (TDT) or non-TDT (NTDT) patients treated with both formulations in a sequential manner. The primary endpoint was patient-reported preference for FCT over DT, while secondary outcomes included patient reported outcomes (PROs) evaluated by overall preference, and by age, thalassemia transfusion status, and previous ICT status. Out of 183 patients screened, 140 and 136 patients completed the treatment periods 1 and 2 of the core study, respectively. At week 48, the majority of patients preferred FCT over DT (90.3 vs. 7.5%; difference of percentage: 0.83 [95% confidence interval (CI), 0.75-0.89; P < 0.0001]). FCT scored better on secondary PROs and showed less severe gastrointestinal symptoms than DT, except in the change of modified Satisfaction with Iron Chelation Therapy (mSICT) preference scores, which were similar for both the formulations. Patients with TDT had stable ferritin levels, while it showed a downward trend up to week 48 in patients with NTDT on deferasirox treatment. Overall, 89.9% of patients reported ≥ 1 adverse event (AE), of which 20.3% experienced ≥ 1 serious AE. The most common treatment-emergent AEs were proteinuria, pyrexia, urine protein/creatinine ratio increase, diarrhea, upper respiratory tract infections, transaminase increase, and pharyngitis. Overall, this study reinforced the observations from the previous study by showing a distinct patient preference for FCT over DT formulation and further supported the potential benefits of life-long compliance with ICT.
Collapse
Affiliation(s)
- Vip Viprakasit
- Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, 10700, Thailand
| | - Mona M Hamdy
- Clinical Research Center, Cairo University, Cairo, 11562, NA, Egypt
| | - Hoda M A Hassab
- Pediatric Department & Clinical Research Center, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Laila M Sherief
- Faculty of Medicine, Zagazig University, Zagazig Sharqia, 44519, Egypt
| | | | - Mohammed Khattab
- Centre d'Hématologie Et d'oncologie Pédiatrique - CHU Ibn Sina Rabat, 10102, Rabat, Morocco
| | | | - Phu Chi Dung
- Hochiminh City Blood Transfusion Hematology Hospital, Ho Chi Minh City, 700000, Vietnam
| | | | | | - Yamini Sonawane
- Novartis Healthcare Private Limited, Hyderabad, India, 500081
| | | | | | - Ali T Taher
- Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
| |
Collapse
|
5
|
Sykes DA, Salven DS, Tabarestani TQ, Khattab M, Hawary YE, Gadsen J, Bullock WM, Berger M, Abd-El-Barr MM. Awake Spine Surgery: Fad or Future? Egyptian Spine Journal 2023; 41. [DOI: 10.57055/2314-8969.1271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
6
|
Skhoun H, Khattab M, Belkhayat A, Takki Chebihi Z, Bakri Y, Dakka N, El Baghdadi J. Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children. Mol Biol Rep 2022; 49:8291-8300. [PMID: 35705773 DOI: 10.1007/s11033-022-07643-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 05/25/2022] [Indexed: 10/18/2022]
Abstract
BACKGROUND TP53 gene plays a pivotal role in maintaining genetic stability and prevention of malignancies. Alterations of this gene are implicated in more than half of human cancers. To the best of our knowledge, this study is the first to explore TP53 polymorphisms in Moroccan childhood acute lymphoblastic leukemia (ALL). METHODS AND RESULTS DNA samples of 45 ALL children were obtained from peripheral blood. A total of 333 healthy Moroccans were used as controls. Polymerase chain reaction and Sanger sequencing were performed to analyze TP53 hotspot exons in cases. We identified a significant protective effect of the TP53-Arg variant at rs1042522 [OR 0.4593 (0.249-0.8472), p = 0.0127] and the Pro/Arg genotype [OR 0.0350 (0.0047-0.2583), p = 0.0010]. Additionally, we found a novel association between the C-allele of Arg213Arg 1800372 [OR 2.7736 (1.3821-5.5664), p = 0.0041] and the risk of childhood ALL. Importantly, TC/CC genotypes of this polymorphism were revealed to enhance the risk of ALL among females [OR 9.0 (3.1555-25.6693), p < 0.0001]. Arg213Arg was also noticed to be associated with the hemoglobin count of patients at diagnosis by linear regression (p = 0.0318). The analysis of penetrance showed a significant association of the CG/GG genotypes at rs1042522 and TC/CC genotypes at rs1800372 to childhood ALL via dominant model [OR 0.2090 (0.09074-0.4814), p = 0.0002 and OR 3.4205 (1.6084-7.2742), p = 0.0014 for rs1042522 and rs1800372 respectively]. No association was found between TP53 polymorphisms and patients survival. CONCLUSION Altogether, our findings indicated that TP53 polymorphisms are significantly involved in the genetic susceptibility to childhood ALL in Morocco.
Collapse
Affiliation(s)
- Hanaa Skhoun
- Genetics Unit, Military Hospital Mohammed V, Rabat, Morocco.,Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Mohammed Khattab
- Pediatric Hematology and Oncology Center, Children's Hospital, Rabat, Morocco
| | | | | | - Youssef Bakri
- Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Nadia Dakka
- Laboratory of Human Pathologies Biology and Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | | |
Collapse
|
7
|
Matthay KK, Hylton J, Penumarthy N, Khattab M, Soh SY, Nguyen HTK, Alcasabas AP, Fawzy M, Saab R, Khan MS, Ghandour K, Chantada G, Parikh NS, Faulkner L, Lam CG, Howard SC. Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries. Pediatr Blood Cancer 2022; 69:e29568. [PMID: 35084087 DOI: 10.1002/pbc.29568] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 12/24/2021] [Accepted: 01/02/2022] [Indexed: 12/22/2022]
Abstract
BACKGROUND Tumor boards are part of standard care of patients with complex cancers, but appropriate multidisciplinary expertise and infrastructure are often not available in low- and middle-income countries (LMIC) for pediatric cancers, such as neuroblastoma. Our goal was to review results of a Global Neuroblastoma Network (GNN) tumor board accessible to LMIC. METHODS De-identified clinical cases presented via internet conference during a weekly GNN virtual tumor board from 2010 through 2020 were evaluated in a standardized format, including diagnostic imaging, pathology, therapy information, resource limitations, and questions for discussion. Information summarized included the presentations, a survey of the impact on care, and a resource questionnaire. RESULTS Registered GNN participants included 575 individuals from 77 countries, with a median of 39 participants per session. Total 412 cases were presented from 32 countries, including 351 unique neuroblastoma patients, 52 follow-up cases, and nine non-neuroblastoma diagnoses. Twenty-eight educational sessions were presented. Limited critical resources for diagnostics and staging of cases included MYCN analysis (54.7%), metaiodobenzylguanidine (MIBG) scans (38.7%), and International Neuroblastoma Pathology Classification (49%). Therapies were also limited, with markedly decreased use of radiation and autologous stem cell transplant for high-risk cases, and no availability of anti-GD2 antibody in LMIC. Limited sampling with a post-presentation survey showed that 100% found the GNN helpful, and 70% altered the care plan based on the discussion. CONCLUSION This report shows the utility of an international tumor board for LMIC focused on a challenging solid tumor where local expertise may be limited, with international multidisciplinary expert participation and educational sessions.
Collapse
Affiliation(s)
- Katherine K Matthay
- Department of Pediatrics, Benioff Children's Hospital and University of California San Francisco School of Medicine, San Francisco, California, USA
| | - Jennifer Hylton
- Department of Network Development, Resonance Health, Memphis, Tennessee, USA
| | - Neela Penumarthy
- Department of Pediatrics, Kaiser Permanente, Oakland, California, USA
| | - Mohammed Khattab
- Pediatric Hematology-Oncology Center, Children's Hospital, University Mohammed Vth, Rabat, Morocco
| | - Shui Yen Soh
- Pediatric Hematology-Oncology, KK Women and Children's Hospital, Singapore
| | | | - Ana Patricia Alcasabas
- Division of Pediatric Hematology Oncology, University of the Philippines - Philippine General Hospital, Manila, Philippines
| | - Mohammed Fawzy
- Children's Cancer Hospital - Egypt (CCHE/57357) and National Cancer Institute, Cairo University, Cairo, Egypt
| | - Raya Saab
- Children's Cancer Institute, Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon
| | - Muhammad Saghir Khan
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center Al Madinah, Riyadh, Saudi Arabia
| | | | - Guillermo Chantada
- Fundacion Perez-Scremini-Hospital Pereira Rossell, Montevideo, Uruguay and Institute for Translational Research (IIMT) CONICET-Austral University, Pilar, Argentina
| | - Nehal S Parikh
- Department of Pediatrics, Children's Hospital of NJ and Rutgers, New Jersey Medical School, Newark, New Jersey, USA
| | | | - Catherine G Lam
- Departments of Global Pediatric Medicine and Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Scott C Howard
- Acute and Tertiary Care, University of Tennessee Health Science Center College of Medicine Memphis, Memphis, Tennessee, USA
| |
Collapse
|
8
|
Mallon B, Kaboré R, Couitchere L, Akonde FB, Lukamba R, Dackono TA, Narison MLR, Khattab M, Pondy A, Fedhila Ben Ayed F, Budiongo A, Guedenon K, Oberlin O, Patte C. The development of an international childhood cancer hospital register database in 13 African countries. A project of the French African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 2022; 69:e29464. [PMID: 34913572 DOI: 10.1002/pbc.29464] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 10/11/2021] [Accepted: 10/26/2021] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND AIM The establishment of an international hospital-based register (HBR) for the French African Pediatric Oncology Group (GFAOP) was a necessary step in the group's clinical research program. With help from the Sanofi Espoir Foundation's "My Child Matters" program, the GFAOP resolved to develop an international HBR network to collect quality data on children attending the Pediatric Oncology Units (POUs). METHODS All children entering POUs from January 2016 to December 2018 were registered using an online questionnaire. Data collection included information on diagnosis, disease stage, demographics, socioeconomic status, and outcome. An intensive training program was developed to improve both data quality and quantity. RESULTS Among the 3348 children registered, 3230 had a suspected cancer, 681 were not confirmed. A diagnosis was confirmed on radiological, clinical, or histological examination for 2549 children including Burkitt lymphoma (516: 20%)-the most frequent diagnosis, Wilms' tumor (459: 18%), retinoblastoma (357: 14%), and acute lymphoblastic leukemia (345: 13%). Of these, 2187 children were treated. Early deaths, abandonment, economic difficulties, and lack of equipment were some of the reasons offered to explain the numbers of undiagnosed and untreated children. Vital status is known for 1994 children: 1187 died and 807 were alive, 551 of these with a follow-up > 12 months. CONCLUSION This work has provided reliable data on children attending the POUs, especially clarifying reasons and occasions for care rupture. The data will help to identify material, human resources, and staff training needs, to evaluate progress, and to encourage consideration of pediatric cancer in national cancer plans.
Collapse
Affiliation(s)
| | - Rolande Kaboré
- Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso
| | | | | | - Robert Lukamba
- Cliniques Universitaires de Lubumbashi (CUL) Democratic Republic of Congo (DRC)
| | | | | | | | - Angèle Pondy
- Centre Mère et Enfant de la Fondation Chantal Biya, Yaoundé, Cameroon
| | | | | | - Koffi Guedenon
- Unité d'oncologie pédiatrique, CHU Sylvanus Olympio, Lomé, Togo
| | | | | |
Collapse
|
9
|
Salman MA, Salman A, Elewa A, Rabiee A, Tourky M, Shaaban HED, Issa M, AbdAlla A, Khattab M, Refaat A, Fathy E, Mohamed US, Noureldin K, Moustafa A, Elias AAK, Elmarzouky MS, Shazly MN, Omar HSE. Secondary Hyperparathyroidism Before and After Bariatric Surgery: a Prospective Study with 2-Year Follow-Up. Obes Surg 2022; 32:1141-1148. [PMID: 35050483 DOI: 10.1007/s11695-022-05902-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 01/07/2022] [Accepted: 01/14/2022] [Indexed: 10/19/2022]
Abstract
PURPOSE Secondary hyperparathyroidism (SHPT) is linked to obesity. Bariatric surgery may be associated with calcium and vitamin D deficiencies leading to SHPT. This study aimed to detect the prevalence of SHPT before and after bariatric surgery. METHODS This prospective study assessed the prevalence of SHPT after sleeve gastrectomy (SG, n = 38) compared to one-anastomosis gastric bypass (OAGB, n = 86). All patients were followed up for 2 years. Bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry. RESULTS Of the 124 patients, 71 (57.3%) were females, and 53 (42.7%) were males, with a mean age of 37.5 ± 8.8 years. Before surgery, 23 patients (18.5%) suffered from SHPT, and 40 (32.3%) had vitamin D deficiency. The prevalence of SHPT increased to 29.8% after 1 year and 36.3% after 2 years. SHPT was associated with lower levels of vitamin D and calcium and higher reduction of BMD in the hip but not in the spine. After 2 years, SHPT was associated with a significantly lower T-score in the hip. SHPT and vitamin D deficiency were significantly more common in patients subjected to OAGB compared to SG (p = 0.003, and p < 0.001, respectively). There is a strong negative correlation between vitamin D levels and parathormone levels before and after surgery. CONCLUSION Prevalence of SHPT is high in obese patients seeking bariatric surgery, especially with lower vitamin D levels. Bariatric surgery increases the prevalence of SHPT up to 2 years. Gastric bypass is associated with a higher risk of developing SHPT compared to SG.
Collapse
Affiliation(s)
- Mohamed AbdAlla Salman
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt.
| | - Ahmed Salman
- Internal Medicine Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Ahmed Elewa
- General Surgery Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
| | - Ahmed Rabiee
- Internal Medicine Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Mohamed Tourky
- General Surgery Department, Great Western Hospital, NHS Foundation Trust, Swindon, UK
| | - Hossam El-Din Shaaban
- Gastroenterology and Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
| | - Mohamed Issa
- Prince Charles Hospital, Myrthyer Tydfil, Cardiff, UK
| | - Ahmed AbdAlla
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Mohammed Khattab
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Ahmed Refaat
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Ehab Fathy
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Usama Shaker Mohamed
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Khaled Noureldin
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Ahmed Moustafa
- Endemic Medicine and Hepatology Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Abd Al-Kareem Elias
- Department of General Surgery, Faculty of Medicine, Al-Azhar University, Assuit Branch, Assuit, Egypt
| | | | - Mohamed Nasr Shazly
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| | - Haitham S E Omar
- General Surgery Department, Kasralainy School of Medicine, Cairo University, Cairo, Egypt
| |
Collapse
|
10
|
Skhoun H, Khattab M, Chebihi ZT, Belkhayat A, Dakka N, BaghdadI JE. B/T mixed phenotype acute leukemia with high hyperdiploidy and lineage switch to B-cell acute leukemia. Leuk Res Rep 2022; 17:100289. [PMID: 35079568 PMCID: PMC8777379 DOI: 10.1016/j.lrr.2022.100289] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 11/03/2021] [Accepted: 01/14/2022] [Indexed: 11/16/2022] Open
Abstract
Acute leukemias are often of myeloid or lymphoid origin. However, some acute leukemias revealed an undefined differentiation into a single lineage. Mixed phenotype acute leukemia (MPAL) is an uncommon diagnosis were blasts can share B/T/myeloid phenotype. Here, we report a rare case of a 17-year-old Moroccan female diagnosed with B/T mixed phenotype acute leukemia and a high hyperdiploid karyotype who relapsed after one year of complete remission with a lineage switch to B-cell acute lymphoblastic leukemia. This case report corroborates the disclosed findings about the high occurence of abnormal karyotypes and poor prognosis of MPAL.
Collapse
Affiliation(s)
- Hanaa Skhoun
- Genetics Unit, Military Hospital Mohammed V, Rabat, Morocco
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, and Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabar, Morocco
| | - Mohammed Khattab
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | | | | | - Nadia Dakka
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, and Genomic Center of Human Pathologies, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabar, Morocco
| | | |
Collapse
|
11
|
Skhoun H, Khattab M, Belkhayat A, Takki Chebihi Z, Dakka N, El Baghdadi J. A prognostic approach on a case of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy-7. Clin Case Rep 2021; 9:e05207. [PMID: 34963805 PMCID: PMC8710846 DOI: 10.1002/ccr3.5207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 11/04/2021] [Accepted: 11/14/2021] [Indexed: 11/21/2022] Open
Abstract
In this work, we present the first case of a Ph-positive ALL Moroccan girl with t(9;22)(q34;q11) and monosomy-7. She was diagnosed with Ph-positive ALL based on bone marrow examination, immunophenotyping, and cytogenetic analysis. She relapsed after treatment with the persistence of the Ph chromosome and the appearance of a monosomy-7.
Collapse
Affiliation(s)
- Hanaa Skhoun
- Genetics UnitMilitary Hospital Mohammed VRabatMorocco
- Laboratory of Human Pathologies BiologyGenomic Center of Human PathologiesFaculty of SciencesMohammed V University in RabatRabatMorocco
| | - Mohammed Khattab
- Department of Pediatric Hemato‐OncologyChildren's Hospital of RabatRabatMorocco
| | | | | | - Nadia Dakka
- Laboratory of Human Pathologies BiologyGenomic Center of Human PathologiesFaculty of SciencesMohammed V University in RabatRabatMorocco
| | | |
Collapse
|
12
|
Ahmed L, El-Mokadem B, Khattab M, El-Abhar H. Quercetin enhances the efficacy of telmisartan in myocardial ischaemia/reperfusion injury in rats. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The clinical outcome of myocardial ischaemia/reperfusion (I/R) injury is still unpredictable and detrimental despite the use of several agents including renin-angiotensin system inhibitors. Quercetin (QN), one of the most prevalent flavonoids, has attracted great attention in the recent years due to its protective role against I/R injury. Interestingly, a recent experimental study showed an important role for β-catenin in the regulation of myocardial I/R injury following heterotopic heart transplantation.
Purpose
The present investigation was directed to estimate the role GSK-3β/β-catenin signaling as a possible mechanistic pathway, through which QN could modulate the therapeutic effect of telmisartan (Tel) in myocardial I/R injury in rats.
Methods
Myocardial I/R was induced by ligation of the left descending coronary artery for 30 min followed by reperfusion for 2 h. Rats were pretreated with Tel (12 mg/kg/day, po), QN (25 mg/kg/day) or a combination of both agents for 3 days before the experiment. Electrocardiographic abnormalities were assessed at the end of ischemic and reperfusion periods. Animals were then sacrificed to assess the cardiac injury surrogate markers; viz., serum CK-MB and cTn-I levels and cardiac energy content (ATP) as well as oxidative stress (ROS, MDA, SOD and TAC), inflammation-related (TNF-α, NF-κB, ICAM-1 and MPO) and apoptotic markers (caspase 3 and Bcl-2). Moreover, the hallmark of fibrosis (TGF-β1) was estimated in addition to GSK-3β/β-catenin signaling. Finally, histological examinations were performed to assess the severity of myocardial damage.
Results
Combined Tel/QN therapy showed an additional improvement compared to each therapy alone (p<0.05) toward reducing myocardial I/R-induced oxidative stress, inflammatory, fibrogenic, and apoptotic markers which subsequently restored Wnt/β-catenin signaling through inhibition of GSK-3β upregulation together with spiking up of β-catenin content. All these changes were associated with restoration of myocardial energy content and prevention of I/R-induced damage in histological examination.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- L Ahmed
- Cairo university, Cairo, Egypt
| | - B El-Mokadem
- Faculty of Pharmacy, Ahram Canadian University, Pharmacology and Toxicology, Giza, Egypt
| | | | | |
Collapse
|
13
|
Sarhan MD, Khattab M, Sarhan MD, Maurice KK, Hassan H. Impact of Bariatric Surgery on Male Sexual Health: a Prospective Study. Obes Surg 2021; 31:4064-4069. [PMID: 34169483 DOI: 10.1007/s11695-021-05522-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/28/2021] [Accepted: 06/08/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Obesity is a worldwide prevalent problem which negatively affects most of the human body systems. Male sexual dysfunction is a frequent problem in obese individuals. Nowadays, bariatric surgery is the most successful way for the management of morbid obesity. Recent research has concluded that it has a significant improving effect on sexual function. AIM OF THE STUDY This study aimed to assess the long-term effect of bariatric surgery on male sexual function. PATIENTS AND METHODS Sixty-six male patients indicated for bariatric surgery were enrolled in this prospective study. Only forty-eight of them completed the study. Patients were invited to fill the International Index of Erectile Function (IIEF) questionnaire twice, preoperatively (T1) and 12 months postoperatively (T2). Simultaneously, patients' serum testosterone levels were assayed. RESULTS At T2, the patients showed highly significant increase in the IIEF scores and the serum testosterone levels (p<0.001). Only weight and BMI were significant predictors of the IIEF scores. The same factors as well as the patients' age were predictors of the serum testosterone levels. CONCLUSION Bariatric surgery improves male sexual health. It is associated with significant increase in IIEF score and serum testosterone levels.
Collapse
Affiliation(s)
- Mohamed D Sarhan
- Department of General Surgery, Kasr Alainy Hospital, Cairo University, Elmanial, Cairo, Egypt
| | - Mohammed Khattab
- Department of General Surgery, Kasr Alainy Hospital, Cairo University, Elmanial, Cairo, Egypt
| | - Mai D Sarhan
- Department of Family Medicine, Kasr Alainy Hospital, Cairo University, Elmanial, Cairo, Egypt
| | - Karim K Maurice
- Department of General Surgery, Kasr Alainy Hospital, Cairo University, Elmanial, Cairo, Egypt.
| | - Haitham Hassan
- Department of General Surgery, Kasr Alainy Hospital, Cairo University, Elmanial, Cairo, Egypt
| |
Collapse
|
14
|
Khattab M, El-Sallak M, Morcos SM, Salama A. Heat transfer and pressure drop for air-water mixtures in an isoflux vertical annulus / Wärmeübertragung und Druckabfall für Strömungen von Luft-Wasser-Gemischen in einem vertikalen Ringraum. KERNTECHNIK 2021. [DOI: 10.1515/kern-1996-612-310] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Abstract
BACKGROUND To date, there has been limited work evaluating the total cumulative effective radiation dose received by infants in the neonatal intensive care unit. Most previous publications report that the total radiation dose received falls within the safe limits but does not include all types of ionizing radiation studies typically performed on this vulnerable patient population. We aimed to provide an estimate of the cumulative effective ionizing radiation dose (cED) in microSieverts (μSv) received by premature infants ≤32 weeks from diagnostic studies performed throughout their NICU stay, and predictors of exposures. METHODS Retrospective chart review from 2004-2011. Data included demographics, gestational age (GA), birth weight (BW), length of stay (LOS), clinical diagnosis, and radiological studies. RESULTS 1045 charts were reviewed. Median GA = 30.0 weeks (SD 2.7, range 22.0-32.6). Median BW = 1340.0 grams (SD 445.4, range 420-2470). Median number of radiographic studies = 9 (SD 28.5, range 0-210). Median cED = 162μSv (range 0-9248). The cED was positively associated with LOS (p < 0.001) and inversely correlated with GA (p < 0.001) and BW (p < 0.001). Infants with intestinal perforation had the highest median cED 1661μSv compared to 162μSv for others (p < 0.001). CONCLUSION Our results provide an estimate of the cumulative effective radiation dose received by premature infants in a level 4 neonatal intensive care unit from all radiological studies involving ionizing radiation and identifies risk factors and predictors of such exposure. Radiation exposure in NICU is highest among the most premature and among infants who suffer from intestinal perforation.
Collapse
Affiliation(s)
- M Khattab
- Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA
| | - J Hagan
- Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA
| | - L H Staib
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - A Mustafa
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - T R Goodman
- Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
16
|
Gad ES, Salama AAA, El-Shafie MF, Arafa HMM, Abdelsalam RM, Khattab M. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats. Inflammation 2020; 43:123-134. [PMID: 31646446 DOI: 10.1007/s10753-019-01101-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive lung damage. Tyrosine kinase inhibitors are approved to treat people with IPF while bone marrow-derived mesenchymal stem cell therapy was previously suggested to inhibit pulmonary fibrosis through the alveolar epithelial cell repair. The present study aimed to evaluate the anti-inflammatory and anti-fibrotic effect of the bone marrow-derived mesenchymal stem cell (BM-MSC) therapy in comparison with nintedanib, a tyrosine kinase inhibitor, on improving survival in bleomycin-induced lung fibrosis in rats. Moreover, the combined therapy of BM-MSCs and nintedanib will be evaluated. In the present study, IPF was induced through intra-tracheal instillation of bleomycin (5 mg/kg) in rats then treatments were administered 14 days thereafter. Nintedanib (100 mg/kg, I.P.) was administered daily for 28 days, while BM-MSCs were injected once intravenously in tail vein in the dose 1 × 106 cells/ml/rat. In the present study, both treatment regimens effectively inhibited lung fibrosis through several pathways, suppressing tumor growth factor-β (TGF-β)/SMAD3 expression which is considered the master signaling pathway. Nintedanib and BLM-MSCs exerted their anti-inflammatory effect through minimizing the expression of TNF-α and IL-6. In addition, the histopathological examination of the lung tissue showed a significant decrease in the alveolar wall thickening, in the inflammatory infiltrate, and in the collagen fiber deposition in response to either nintedanib or BM-MSC and their combination. In conclusion, the therapeutic pulmonary anti-fibrotic activity of nintedanib or BM-MSC is mediated through their anti-inflammatory properties and inhibition of SMAD-3/TGF-β expression.
Collapse
Affiliation(s)
- E S Gad
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
| | - A A A Salama
- Department of Pharmacology, National Research Centre, Cairo, Egypt
| | - M F El-Shafie
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt
| | - H M M Arafa
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Ahram Canadian University, Cairo, Egypt
| | - R M Abdelsalam
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - M Khattab
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| |
Collapse
|
17
|
El Kababri M, Benmiloud S, Cherkaoui S, El Houdzi J, Maani K, Ansari N, Khoubila N, Kili A, El Khorassani M, Madani A, Tazi MA, Ahid S, Hessissen L, Quessar A, Harif M, Khattab M, André N. Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies. Pediatr Blood Cancer 2020; 67:e28508. [PMID: 32658380 DOI: 10.1002/pbc.28508] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 05/05/2020] [Accepted: 05/26/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND In low- and middle-income countries, therapeutic options for advanced, refractory, or relapsing malignancies are limited due to local constraints such as cost of drugs, distance from oncology centers, and lack of availability of new anticancer drugs. Metronomics, which combines metronomic chemotherapy (MC) and drug repositioning, allows for the provision of new therapeutic options for patients in this setting. AIM OF THE STUDY To evaluate the activity and toxicity of a metronomic regimen in Moroccan pediatric patients with refractory or relapsing malignancies. PATIENTS AND METHODS From July 2014 to January 2018, patients with refractory/relapsing solid tumors treated in five pediatric oncology centers were consecutively enrolled. The metronomic regimen consisted of 28-day cycles with daily oral administration of cyclophosphamide (30 mg/m2 ) from days 1 to 21, together with oral etoposide (25 mg/m2 ) from days 1 to 21 followed by break of one week and daily valproic acid (20 mg/kg) from days 1 to 28. RESULTS Ninety-eight children (median age, 8 years) were included. Underlying malignancies were neuroblastoma (24 patients), Ewing sarcoma (18), osteosarcoma (14), rhabdomyosarcoma (14), and miscellaneous tumors (28). A total of 557 cycles were given (median: 6; range, 1-18 cycles). One-year progression-free survival of our patients was 19%, and one-year overall survival was 22%. Complete response was obtained in three cases (3%), partial response in 11 cases (11%), and tumor stabilization for more than six months in 28 cases (28%). CONCLUSION This three-drug metronomic combination was well tolerated and associated with tumor response and disease stabilization in 42 patients even for a long period.
Collapse
Affiliation(s)
- Maria El Kababri
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.,Metronomics Global Health Initiative, Rabat, Morocco
| | - Sarra Benmiloud
- Paediatric Haematology and Oncology Unit, Hospital Hassan II, Fes, Morocco
| | - Siham Cherkaoui
- Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco
| | - Jamila El Houdzi
- Pediatic Haematology and Oncology Unit, Hospital Mohamed VI, Marrakech, Morocco
| | - Khadija Maani
- Paediatric Haematology and Oncology Unit, Hospital Ibn Rochd, Casablanca, Morocco
| | - Nawal Ansari
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco
| | - Nissrine Khoubila
- Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco
| | - Amina Kili
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco
| | - Mohammed El Khorassani
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco
| | - Abdellah Madani
- Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco
| | | | - Samir Ahid
- Pharmacoeconomics and Pharmacoepidemiology Research Team, Mohammed V University, Rabat, Morocco.,Laboratory of Biostatistics, Clinical and Epidemiological Research, Mohammed V University, Rabat, Morocco
| | - Laila Hessissen
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco.,Metronomics Global Health Initiative, Rabat, Morocco
| | - Asmaa Quessar
- Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco
| | - Mhamed Harif
- Paediatric Haematology and Oncology Service, Hospital 20 Aout, Casablanca, Morocco
| | - Mohammed Khattab
- Paediatric Haematology and Oncology Center, Children's Hospital of Rabat, Mohammed V University, Rabat, Morocco
| | - Nicolas André
- Paediatric Haematology and Oncology Department, La Timone Children's Hospital, Assistance Publique Hopitaux de Marseille, Marseille, France.,SMARTc Unit, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix Marseille Univ, Marseille, France.,Metronomics Global Health Initiative, Marseille, France
| |
Collapse
|
18
|
Saab R, Obeid A, Gachi F, Boudiaf H, Sargsyan L, Al-Saad K, Javakhadze T, Mehrvar A, Abbas SS, Abed Al-Agele YS, Al-Haddad S, Al Ani MH, Al-Sweedan S, Al Kofide A, Jastaniah W, Khalifa N, Bechara E, Baassiri M, Noun P, El-Houdzi J, Khattab M, Sagar Sharma K, Wali Y, Mushtaq N, Batool A, Faizan M, Raza MR, Najajreh M, Mohammed Abdallah MA, Sousan G, Ghanem KM, Kocak U, Kutluk T, Demir HA, Hodeish H, Muwakkit S, Belgaumi A, Al-Rawas AH, Jeha S. Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranean (POEM) group. Cancer 2020; 126:4235-4245. [PMID: 32648950 PMCID: PMC7404449 DOI: 10.1002/cncr.33075] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 06/06/2020] [Accepted: 06/12/2020] [Indexed: 01/22/2023]
Abstract
Background Childhood cancer is a highly curable disease when timely diagnosis and appropriate therapy are provided. A negative impact of the coronavirus disease 2019 (COVID‐19) pandemic on access to care for children with cancer is likely but has not been evaluated. METHODS A 34‐item survey focusing on barriers to pediatric oncology management during the COVID‐19 pandemic was distributed to heads of pediatric oncology units within the Pediatric Oncology East and Mediterranean (POEM) collaborative group, from the Middle East, North Africa, and West Asia. Responses were collected on April 11 through 22, 2020. Corresponding rates of proven COVID‐19 cases and deaths were retrieved from the World Health Organization database. Results In total, 34 centers from 19 countries participated. Almost all centers applied guidelines to optimize resource utilization and safety, including delaying off‐treatment visits, rotating and reducing staff, and implementing social distancing, hand hygiene measures, and personal protective equipment use. Essential treatments, including chemotherapy, surgery, and radiation therapy, were delayed in 29% to 44% of centers, and 24% of centers restricted acceptance of new patients. Clinical care delivery was reported as negatively affected in 28% of centers. Greater than 70% of centers reported shortages in blood products, and 47% to 62% reported interruptions in surgery and radiation as well as medication shortages. However, bed availability was affected in <30% of centers, reflecting the low rates of COVID‐19 hospitalizations in the corresponding countries at the time of the survey. Conclusions Mechanisms to approach childhood cancer treatment delivery during crises need to be re‐evaluated, because treatment interruptions and delays are expected to affect patient outcomes in this otherwise largely curable disease. The response to the coronavirus disease 2019 (COVID‐19) pandemic has led to significant alterations in access to care for children with cancer. Interventions are needed to mitigate the effects on life‐threatening diseases requiring immediate and uninterrupted therapy, such as childhood cancer.
Collapse
Affiliation(s)
- Raya Saab
- Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Anas Obeid
- Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Fatiha Gachi
- Department of Pediatrics, Pierre and Marie Curie Center, Algiers, Algeria
| | - Houda Boudiaf
- Department of Pediatrics, Mustapha Pacha Hospital, Moustapha, Algeria
| | - Lilit Sargsyan
- Pediatric Cancer and Blood Disorders Center of Armenia, Professor R.H. Yeolyan Hematology Center, Yerevan, Armenia
| | - Khulood Al-Saad
- Department of Pediatrics, Salmaniya Medical Complex, Manama, Bahrain
| | - Tamar Javakhadze
- Department of Pediatrics, Iashvili Children's Central Hospital, Tbilisi, Georgia
| | - Azim Mehrvar
- MAHAK Pediatric Cancer Treatment and Research Center, Tehran, Iran
| | - Sawsan Sati Abbas
- Department of Pediatrics, Al-Imamian Al-Kadhimiyain Medical City, Baghdad, Iraq
| | | | - Salma Al-Haddad
- Department of Pediatrics, Children Welfare Teaching Hospital, Medical City, Baghdad, Iraq
| | | | - Suleiman Al-Sweedan
- Department of Pediatrics, King Abdullah University Hospital, Ar Ramtha, Jordan
| | - Amani Al Kofide
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia
| | - Wasil Jastaniah
- Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, Kingdom of Saudi Arabia.,College of Medicine, Umm AlQura University, Makkah, Kingdom of Saudi Arabia
| | - Nisreen Khalifa
- National Bank of Kuwait Children's Hospital, Kuwait City, Kuwait
| | - Elie Bechara
- Department of Pediatrics, Lebanese Hospital Geitaoui, Beirut, Lebanon
| | - Malek Baassiri
- Department of Pediatrics, Makassed General Hospital, Beirut, Lebanon.,Department of Pediatrics, Hammoud Hospital University Medical Center, Saida, Lebanon
| | - Peter Noun
- Department of Pediatrics, St George Hospital University Medical Center, Beirut, Lebanon
| | - Jamila El-Houdzi
- Department of Pediatric Hematology-Oncology, Mohammed VI Marrakech University Hospital Center, Marrakech, Morocco
| | - Mohammed Khattab
- Pediatric Hematology and Oncology Center, Ibn Sina University Hospital Center, Rabat, Morocco
| | - Krishna Sagar Sharma
- Department of Medical Oncology, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal
| | - Yasser Wali
- Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman
| | - Naureen Mushtaq
- Department of Pediatrics, Aga Khan University Hospital, Karachi, Pakistan
| | - Aliya Batool
- Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan
| | - Mahwish Faizan
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, The Children's Hospital and the Institute of Child Health, Lahore, Pakistan
| | | | - Mohammad Najajreh
- Huda Al Masri Pediatric Cancer Department, Beit Jala Governmental Hospital, Beit Jala, Palestine
| | | | - Ghada Sousan
- Department of Pediatrics, Al Bairouni Hospital, Damascus, Syria
| | - Khaled M Ghanem
- Basma Pediatric Oncology Unit, Al Bairouni Hospital, Damascus, Syria
| | - Ulker Kocak
- Department of Pediatrics, Gazi University Hospital, Ankara, Turkey
| | - Tezer Kutluk
- Department of Pediatric Oncology, Hacettepe University Cancer Institute and Faculty of Medicine, Ankara, Turkey
| | - Hacı Ahmet Demir
- Department of Pediatric Hematology-Oncology, Private Memorial Ankara Hospital, Ankara, Turkey
| | - Hamoud Hodeish
- Pediatric Oncology Department, National Oncology Center, Sana'a, Yemen
| | - Samar Muwakkit
- Children's Cancer Institute, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - Asim Belgaumi
- Department of Pediatrics, Aga Khan University Hospital, Karachi, Pakistan
| | | | - Sima Jeha
- Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee
| |
Collapse
|
19
|
Zayat R, Ahmad U, Twarie L, Moza A, Schaelte G, Allham O, Haneya A, Khattab M, Schnoering H, Autschbach R. Combining Ultrafast Anaesthesia and Minimal Invasive Implantation in HeartMate 3: A Pilot Study. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
20
|
Khoubila N, Bendari M, Benmiloud S, ElHoudzi J, Maani K, Elmouden L, Alzemmouri M, Hachim J, Kili A, Kababri M, Khattab M, ElBouri H, Hassoune S, Nani S, Cherkaoui S, Quessar A, Madani A, Hessissen L. Pain Management in Children with Cancer: National Surveys of Practices and Perceptions in Morocco. Open Access Maced J Med Sci 2020. [DOI: 10.3889/oamjms.2020.5252] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
AIM: The aim of the study was to improve the quality of pain management in Moroccan pediatric oncology units, the Moroccan Society of Paediatric Haematology/Oncology initiated a national quality improvement project in 2014 with the support of the Lalla Salma Foundation for Prevention and Treatment of Cancer.
METHODS: To assess the current situation of pain management in Moroccan pediatric oncology patients, two cross-sectional surveys were conducted, involving patient/parental proxies and health-care providers’.
RESULTS: The first survey concerned 108 care providers from five institutions. The second survey covered 155 children with cancer from the five Moroccan pediatric oncology units. Among them, 145 reported suffering from pain, which patients/families attributed to the underlying cancer (n = 85), to procedures and treatment (n = 46), or to both the cancer and procedures/treatment (n = 19). Procedural pain was mainly related to lumbar puncture and bone marrow aspirate. The majority of patients/parents reported that pain negatively impacted their emotional, physical, and social functioning. The majority of parents requested further information and communication about pain management.
CONCLUSION: Both health-care providers and families of children with cancer in Morocco report need for pain management improvement, including in institutional and educational practices. This current baseline data have informed the development of our ongoing project including continuing education, training, and practice policies development.
Collapse
|
21
|
Ahmed AM, Mohammed AT, Vu TT, Khattab M, Doheim MF, Ashraf Mohamed A, Abdelhamed MM, Shamandy BE, Dawod MT, Alesaei WA, Kassem MA, Mattar OM, Smith C, Hirayama K, Huy NT. Prevalence and burden of dengue infection in Europe: A systematic review and meta‐analysis. Rev Med Virol 2019; 30:e2093. [DOI: 10.1002/rmv.2093] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 11/11/2019] [Accepted: 11/12/2019] [Indexed: 12/29/2022]
Affiliation(s)
| | | | - Thao T. Vu
- School of Health and Biomedical SciencesRMIT University Melbourne Victoria Australia
| | | | | | | | | | | | | | - Wafaa Ali Alesaei
- Faculty of MedicineMisr University for Science and Technology Giza Egypt
| | - Mahmoud Attia Kassem
- Medical Oncology DepartmentThe Ohio State University Wexner Medical Center Columbus Ohio USA
| | | | - Chris Smith
- School of Tropical Medicine and Global HealthNagasaki University Nagasaki Japan
- Department of Clinical ResearchLondon School of Hygiene and Tropical Medicine London UK
| | - Kenji Hirayama
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), School of Tropical Medicine and Global HealthNagasaki University Nagasaki Japan
| | - Nguyen Tien Huy
- Evidence Based Medicine Research GroupTon Duc Thang University Ho Chi Minh City Vietnam
- Faculty of Applied SciencesTon Duc Thang University Ho Chi Minh City Vietnam
| |
Collapse
|
22
|
Khalil AH, Khattab M, Hosny KA, Elshazly M, Salah Eldin A, Hosny A. Effect of Portal Venous Pressure on Liver Function of Donors in Living Donor Liver Transplantation. Ann Transplant 2019; 24:401-406. [PMID: 31273186 PMCID: PMC6636408 DOI: 10.12659/aot.916038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background We assessed the alterations in portal hemodynamics associated with donor right hepatectomy and its effects on functional regeneration of the remnant liver. Material/Methods This prospective study included 30 adult living donors who underwent right hepatectomy in the Liver Transplantation Unit, Faculty of Medicine, Cairo University from June 2015 to October 2016. During donor surgery, portal venous pressure (PVP) was measured using an antithrombotic catheter inserted into the main portal vein, and was measured before and after clamping of the right portal vein. Postoperatively, liver function tests were done daily until normalization. The outcome measures were the time to normalization of liver function tests and effect of residual volume and steatosis on PVP. Results All donors had normal PVP before clamping and changed significantly after clamping (p<0.001). After clamping, 25 donors (83%) had a PVP above 12 mmHg; i.e. had high portal pressure. The median percentage of change was 55%. There were obvious increases in liver enzymes and bilirubin after surgery, but albumin and international normalized ratio showed progressive decreases postoperatively. The percent change in PVP was positively correlated with the levels of liver enzymes, time to normalization of liver enzymes, albumin, and bilirubin, and with the degree of steatosis, bit it was negatively correlated with residual liver volume. Conclusions During living donor liver transplantation, PVP increases by over 50% after clamping of the right portal vein of the donor’s liver. This increase is associated with temporary delay of normalization of liver function of the donors.
Collapse
Affiliation(s)
- Ahmed H Khalil
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Mohammed Khattab
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Karim A Hosny
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Mostafa Elshazly
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Ayman Salah Eldin
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Adel Hosny
- Department of General Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt
| |
Collapse
|
23
|
Farghali H, AbdElkader N, AbuBakr H, Elhelw R, Khattab M. Assessment of autologous platelet-rich plasma infiltration on the healing of skin wounds infected with methicillin-resistant Staphylococcus aureus (mrsa) in dogs. J Comp Pathol 2019. [DOI: 10.1016/j.jcpa.2018.10.163] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
24
|
Lauermann P, Feltgen N, Khattab M, Storch M, Hoerauf H. Zunehmende Lipidexsudation und Gefäßveränderungen assoziiert mit einem Aderhautnävus. Ophthalmologe 2018; 115:1066-1069. [DOI: 10.1007/s00347-018-0652-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Chebihi ZT, Belkhayat A, Chadli E, Hessissen L, El Khorassani M, El Kababri M, Kili A, Khattab M, Bakri Y, Dakka N. The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia. Leuk Res Rep 2018; 11:1-4. [PMID: 30533380 PMCID: PMC6260455 DOI: 10.1016/j.lrr.2018.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 10/08/2018] [Accepted: 11/21/2018] [Indexed: 11/04/2022] Open
Abstract
Cytogenetic studies of acute lymphoblastic leukemia have been at the forefront of research in the pathogenesis of cancer. The presence of recurring chromosomal abnormalities (either numeral or structural rearrangements) provides immediate clues to the genetic events leading to leukemia and many abnormalities have important prognostic significance. The rare translocation t(14,21)(q11.2;q22) has been described in pediatric T lineage ALL in only one case so far in 2000. The present study is a case report of an ALL case in which we found a t(14,21)(q11.2;q22) as a non random chromosomal abnormality among 70 analyzed pediatric ALL cases referred exclusively to BIOLAB Laboratory from the children hospital of Morocco.
Collapse
Affiliation(s)
- Z Takki Chebihi
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.,BIOLAB Laboratory, Rabat, Morocco
| | | | - E Chadli
- BIOLAB Laboratory, Rabat, Morocco
| | - L Hessissen
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Morocco
| | - M El Khorassani
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Morocco
| | - M El Kababri
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Morocco
| | - A Kili
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Morocco
| | - M Khattab
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Morocco
| | - Y Bakri
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - N Dakka
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| |
Collapse
|
26
|
Abstract
Childhood cancer and its invasive treatment is a distressing life experience for the child and his family. Providing informational support is an essential part of community care, and defining parent's burden is an important part of this goal. However, providing such information can be particularly challenging in Arab countries where beliefs, traditions, religion, and socioeconomic factors influence parents' needs and their priorities of needs. This article presents a review of these specificities among Arab families. Implications of health-care providers are also discussed.
Collapse
Affiliation(s)
- Naïma Otmani
- Pediatric Hematology and Oncology Unit, Children Hospital of Rabat, Rabat, Morocco.
| | - Mohammed Khattab
- Pediatric Hematology and Oncology Unit, Children Hospital of Rabat, Rabat, Morocco.
| |
Collapse
|
27
|
Chebihi ZT, Belkhayat A, Chadli E, Hilal L, Skhoun H, Hessissen L, El Khorassani M, El Kababri M, Kili A, Khattab M, Bakri Y, Dakka N. Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature. Clin Lymphoma Myeloma Leuk 2018; 18:e241-e248. [PMID: 29748040 DOI: 10.1016/j.clml.2018.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 04/19/2018] [Indexed: 11/17/2022]
Abstract
BACKGROUND Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, with a peak incidence at 2 to 3 years of age and accounting for almost 30% of all cancers in this age group. It is well established that the identification of cytogenetic abnormalities is highly relevant for the prognosis of and therapeutic decisions in ALL. The purpose of the present study was to define the frequency of recurrent chromosomal abnormalities of ALL in Moroccan patients referred exclusively to the BIOLAB Laboratory of the Children's Hospital of Rabat during a 4-year period and compare our findings to the reported data. PATIENTS AND METHODS We performed conventional karyotyping of 155 ALL cases, with a successful cell culture rate of 94%. RESULTS We identified chromosomal abnormalities in 66% of the total studied cases, of which 70% revealed important recurrent abnormalities with high prognostic value, such as hyperdiploidy, hypodiploidy, t(9;22), t(8;14), t(1;19), and MLL rearrangements. In total agreement with the reported data, most of the patients (56%) in the present study were aged 1 to 5 years, with a male predominance, and B-ALL was the most common blast phenotype (85%). CONCLUSION The frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data.
Collapse
Affiliation(s)
- Zahra Takki Chebihi
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco; BIOLAB Laboratory, Rabat, Morocco.
| | | | | | - Latifa Hilal
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Hanaa Skhoun
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Laila Hessissen
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | - Mohamed El Khorassani
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | - Maria El Kababri
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | - Amina Kili
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | - Mohammed Khattab
- Department of Pediatric Hemato-Oncology, Children's Hospital of Rabat, Rabat, Morocco
| | - Youssef Bakri
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| | - Nadia Dakka
- Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco
| |
Collapse
|
28
|
Sefsafi Z, Hasbaoui BE, Kili A, Agadr A, Khattab M. Macrophage activation syndrome associated with griscelli syndrome type 2: case report and review of literature. Pan Afr Med J 2018; 29:75. [PMID: 29875956 PMCID: PMC5987098 DOI: 10.11604/pamj.2018.29.75.12353] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Accepted: 12/19/2017] [Indexed: 11/13/2022] Open
Abstract
Macrophage activation syndrome (MAS) is a severe and potentially fatal life-threatening condition associated with excessive activation and expansion of T cells with macrophages and a high expression of cytokines, resulting in an uncontrolled inflammatory response, with high levels of macrophage colony-stimulating factor and causing multiorgan damage. This syndrome is classified into primary (genetic/familial) or secondary forms to several etiologies, such as infections, neoplasias mainly hemopathies or autoimmune diseases. It is characterised clinically by unremitting high fever, pancytopaenia, hepatosplenomegaly, hepatic dysfunction, encephalopathy, coagulation abnormalities and sharply increased levels of ferritin. The pathognomonic feature of the syndrome is seen on bone marrow examination, which frequently, though not always, reveals numerous morphologically benign macrophages exhibiting haemophagocytic activity. Because MAS can follow a rapidly fatal course, prompt recognition of its clinical and laboratory features and immediate therapeutic intervention are essential. However, it is difficult to distinguish underlying disease flare, infectious complications or medication side effects from MAS. Although, the pathogenesis of MAS is unclear, the hallmark of the syndrome is an uncontrolled activation and proliferation of T lymphocytes and macrophages, leading to massive hypersecretion of pro-inflammatory cytokines. Mutations in cytolytic pathway genes are increasingly being recognised in children who develop MAS in his secondary form. We present here a case of Macrophage activation syndrome associated with Griscelli syndrome type 2 in a 3-years-old boy who had been referred due to severe sepsis with non-remitting high fever, generalized lymphoadenopathy and hepato-splenomegaly. Laboratory data revealed pancytopenia with high concentrations of triglycerides, ferritin and lactic dehydrogenase while the bone marrow revealed numerous morphologically benign macrophages with haemophagocytic activity that comforting the diagnosis of a SAM according to Ravelli and HLH-2004 criteria. Griscelli syndrome (GS) was evoked on; consanguineous family, recurrent infection, very light silvery-gray color of the hair and eyebrows, Light microscopy examination of the hair showed large, irregular clumps of pigments characteristic of GS. The molecular biology showed mutation in RAB27A gene confirming the diagnosis of a Griscelli syndrome type 2. The first-line therapy was based on the parenteral administration of high doses of corticosteroids, associated with immunosuppressive drugs, cyclosporine A and etoposide waiting for bone marrow transplantation (BMT).
Collapse
Affiliation(s)
- Zakia Sefsafi
- Center for Hematology and Oncology Paediatrics, Children's hospital, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco
| | - Brahim El Hasbaoui
- Department of Pediatrics, Military Teaching Hospital Mohammed V, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco
| | - Amina Kili
- Center for Hematology and Oncology Paediatrics, Children's hospital, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco
| | - Aomar Agadr
- Department of Pediatrics, Military Teaching Hospital Mohammed V, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco
| | - Mohammed Khattab
- Center for Hematology and Oncology Paediatrics, Children's hospital, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco
| |
Collapse
|
29
|
Mohammed AT, Khattab M, Ahmed AM, Turk T, Sakr N, M Khalil A, Abdelhalim M, Sawaf B, Hirayama K, Huy NT. The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials. Clin Rheumatol 2017; 36:2697-2707. [PMID: 28914373 DOI: 10.1007/s10067-017-3814-3] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2017] [Revised: 08/20/2017] [Accepted: 08/30/2017] [Indexed: 01/02/2023]
Abstract
Rheumatoid arthritis is an autoimmune disease in which probiotics appears to have an immune modulating action along with decreased inflammatory process. Therefore, we aim to investigate the efficacy of probiotics as an adjuvant therapy for rheumatoid arthritis. A comprehensive literature search was performed using nine databases including PubMed and Web of Science. Interesting data was extracted and meta-analyzed. We assessed the risk of bias using Cochrane Collaboration's tool. The protocol was registered in PROSPERO (CRD 42016036769). We found nine studies involving 361 patients who met our eligibility criteria. Our meta-analysis indicated that pro-inflammatory cytokine IL-6 was significantly lower in the probiotics compared with the placebo group (standardized mean difference = - 0.708; 95% confidence interval (CI) - 1.370 to 0.047, P = 0.036). However, there was no difference between probiotics and placebo in disease activity score (mean difference 0.023; 95% CI - 0.584 to 0.631, P = 0.940). Probiotics lowered pro-inflammatory cytokines IL-6 in RA; however, its clinical effect is still unclear. Hence, many high-quality randomized controlled trials (RCTs) are still needed to prove this effect.
Collapse
Affiliation(s)
| | | | | | - Tarek Turk
- Faculty of Medicine, Damascus University, Damascus, Syria
| | - Nora Sakr
- Faculty of Medicine, Menoufia University, Menoufia, Egypt
| | - Adham M Khalil
- Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt
| | | | - Bisher Sawaf
- Faculty of Medicine, Syrian Private University, Damascus, Syria
| | - Kenji Hirayama
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Nguyen Tien Huy
- Evidence Based Medicine Research Group and Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
- Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
- Center for Molecular Bio-Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, 217 Hong Bang, District 5, Ho Chi Minh, 70000, Viet Nam.
| |
Collapse
|
30
|
Lezrek O, Albaroudi N, Tijani M, Daoudi C, Benchekroun Belabbes I, Khattab M, Tachfouti S, Boutimzine N, Daoudi R. Ophthalmic manifestations in hepatitis-associated aplastic anemia (HAAA): Case report. J Fr Ophtalmol 2017; 40:e231-e233. [DOI: 10.1016/j.jfo.2016.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 03/10/2016] [Accepted: 03/23/2016] [Indexed: 10/19/2022]
|
31
|
Callizo J, Pfeiffer S, Lahme E, van Oterendorp C, Khattab M, Bemme S, Kulanga M, Hoerauf H, Feltgen N. Risk of progression in macula-on rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 2017; 255:1559-1564. [PMID: 28551879 DOI: 10.1007/s00417-017-3696-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 05/04/2017] [Accepted: 05/09/2017] [Indexed: 10/19/2022] Open
Abstract
PURPOSE To identify factors that may lead to a rapid progression in macula-on rhegmatogenous retinal detachment (RRD), in particular, those that may lead to macular involvement. METHODS Observational, prospective, single-center study. Patients referred for surgery due to primary rhegmatogenous retinal detachment with the macula on between 2009 and 2013 were included. Relevant factors analyzed included age, time delay until surgery, lens status, myopia, the detachment's location and configuration as well as number, size and type of retinal breaks. Eyes underwent optical coherence tomography to detect macular detachment. A multivariate analysis was performed to investigate the effect of several factors in the progression of retinal detachment. RESULTS A total of 116 eyes of 116 patients were included. Mean time delay between admission and surgery was 1.8 ± 1.4 days. Progression was observed in 19.8% of the eyes. Of those, 47.8% presented macular detachment. Ten of the 11 (90.9%) eyes presenting progression involving the macula also exhibited a bullous configuration, which was the only parameter that correlated significantly with detachment progression in patients with (p = 0.0036) and without (p = 0.0014) macular involvement. CONCLUSIONS For the first time in a prospective trial, a bullous configuration was found to be a highly significant predictor for progression in macula-on detachments. Our data support prompt surgery in patients diagnosed with bullous macula-on RRD.
Collapse
Affiliation(s)
- Josep Callizo
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany.
| | - Sebastian Pfeiffer
- Institute for Clinical Research GmbH, Georg-August University, Goettingen, Germany
| | - Eva Lahme
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Christian van Oterendorp
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Mohammed Khattab
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Sebastian Bemme
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Miroslav Kulanga
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Hans Hoerauf
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| | - Nicolas Feltgen
- Department of Ophthalmology, Georg-August University, Robert-Koch- Str. 40, 37075, Goettingen, Germany
| |
Collapse
|
32
|
Youssef MA, van Wely M, Al-Inany H, Madani T, Jahangiri N, Khodabakhshi S, Alhalabi M, Akhondi M, Ansaripour S, Tokhmechy R, Zarandi L, Rizk A, El-Mohamedy M, Shaeer E, Khattab M, Mochtar MH, van der Veen F. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Hum Reprod 2016; 32:112-118. [PMID: 27836979 DOI: 10.1093/humrep/dew282] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 09/23/2016] [Accepted: 10/10/2016] [Indexed: 11/12/2022] Open
Abstract
STUDY QUESTION In subfertile women with poor ovarian reserve undergoing IVF does a mild ovarian stimulation strategy lead to comparable ongoing pregnancy rates in comparison to a conventional ovarian stimulation strategy? SUMMARY ANSWER A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF leads to similar ongoing pregnancy rates as a conventional ovarian stimulation strategy. WHAT IS KNOWN ALREADY Women diagnosed with poor ovarian reserve are treated with a conventional ovarian stimulation strategy consisting of high-dose gonadotropins and pituitary downregulation with a long mid-luteal start GnRH-agonist protocol. Previous studies comparing a conventional strategy with a mild ovarian stimulation strategy consisting of low-dose gonadotropins and pituitary downregulation with a GnRH-antagonist have been under powered and their effectiveness is inconclusive. STUDY DESIGN, SIZE, DURATION This open label multicenter randomized trial was designed to compare one cycle of a mild ovarian stimulation strategy consisting of low-dose gonadotropins (150 IU FSH) and pituitary downregulation with a GnRH-antagonist to one cycle of a conventional ovarian stimulation strategy consisting of high-dose gonadotropins (450 IU HMG) and pituitary downregulation with a long mid-luteal GnRH-agonist in women of advanced maternal age and/or women with poor ovarian reserve undergoing IVF between May 2011 and April 2014. PARTICIPANTS/MATERIALS, SETTING, METHODS Couples seeking infertility treatment were eligible if they fulfilled the following inclusion criteria: female age ≥35 years, a raised basal FSH level >10 IU/ml irrespective of age, a low antral follicular count of ≤5 follicles or poor ovarian response or cycle cancellation during a previous IVF cycle irrespective of age. The primary outcome was ongoing pregnancy rate per woman randomized. Analyses were on an intention-to-treat basis. We randomly assigned 195 women to the mild ovarian stimulation strategy and 199 women to the conventional ovarian stimulation strategy. MAIN RESULTS AND THE ROLE OF CHANCE Ongoing pregnancy rate was 12.8% (25/195) for mild ovarian stimulation versus 13.6% (27/199) for conventional ovarian stimulation leading to a risk ratio of 0.95 (95% CI: 0.57-1.57), representing an absolute difference of -0.7% (95% CI: -7.4 to 5.9). This 95% CI does not extend below the predefined threshold of 10% for inferiority. The duration of ovarian stimulation was significantly lower in the mild ovarian stimulation strategy than in the conventional ovarian stimulation strategy (mean difference -1.2 days, 95% CI: -1.88 to -0.62). Also, a significantly lower amount of gonadotropins was used in the mild simulation strategy, with a mean difference of 3135 IU (95% CI: -3331 to -2940). LIMITATIONS, REASONS FOR CAUTION A limitation of our study was the lack of data concerning the cryopreservation of surplus embryos, so we are not informed on cumulative pregnancy rates. Another limitation is that we were not able to follow up on the ongoing pregnancies in all centers, so we are not informed on live birth rates. WIDER IMPLICATIONS OF THE FINDINGS The results are directly applicable in daily clinical practice and may lead to considerable cost savings as high dosages of gonadotropins are not necessary in women with poor ovarian reserve undergoing IVF. A health economic analysis of our data planned to test the hypothesis that mild ovarian stimulation strategy is more cost-effective than the conventional ovarian stimulation strategy is underway. STUDY FUNDING/COMPETING INTERESTS This study was supported by NUFFIC scholarship (the Netherlands) and STDF short-term fellowship (Egypt). TRIAL REGISTRATION NUMBER NTR2788 (Trialregister.nl). TRIAL REGISTER DATE 01 March 2011. DATE OF FIRST PATIENT'S ENROLMENT May 2011.
Collapse
Affiliation(s)
- M A Youssef
- Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands .,Department of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, Kasr-Alaini St. El-manial district, Giza, Egypt
| | - M van Wely
- Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
| | - H Al-Inany
- Department of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, Kasr-Alaini St. El-manial district, Giza, Egypt
| | - T Madani
- Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, 2, Hafez St., Banihashem St., Resalat Ave., 16635-148 Tehran, Iran
| | - N Jahangiri
- Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, 2, Hafez St., Banihashem St., Resalat Ave., 16635-148 Tehran, Iran
| | - S Khodabakhshi
- Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, 2, Hafez St., Banihashem St., Resalat Ave., 16635-148 Tehran, Iran
| | - M Alhalabi
- Division of Embryology and Reproductive Medicine, Faculty of Medicine, and Assisted Reproduction Unit, Orient Hospital, Damascus University, Damascus, Syria
| | - M Akhondi
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Shahid Beheshti University, Evin, PO Box 19615-1177 Tehran, Iran
| | - S Ansaripour
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Shahid Beheshti University, Evin, PO Box 19615-1177 Tehran, Iran
| | - R Tokhmechy
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Shahid Beheshti University, Evin, PO Box 19615-1177 Tehran, Iran
| | - L Zarandi
- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Shahid Beheshti University, Evin, PO Box 19615-1177 Tehran, Iran
| | - A Rizk
- Department of Obstetrics & Gynecology, Faculty of Medicine, Banha University, El-Shaheed Farid Nada, Qism Banha, Banha, Al Qalyubia Governorate 13511 Banha, Egypt
| | - M El-Mohamedy
- Department of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, Kasr-Alaini St. El-manial district, Giza, Egypt
| | - E Shaeer
- Department of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, Kasr-Alaini St. El-manial district, Giza, Egypt
| | - M Khattab
- Department of Obstetrics & Gynecology, Faculty of Medicine, Cairo University, Kasr-Alaini St. El-manial district, Giza, Egypt
| | - M H Mochtar
- Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
| | - F van der Veen
- Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands
| |
Collapse
|
33
|
Abstract
Abstract 72 Background: Neuroblastoma is the most common extracranial solid tumor of childhood, accounting for 10% of childhood cancers in high-income countries (HIC), with an unknown incidence in most low- and middle-income countries (LMIC). A multidisciplinary approach to the treatment of high-risk (HR) neuroblastoma consisting of a combination of chemotherapy, surgery, radiation and immunotherapy, has lead to improvements in survival in HICs, approaching 40-50%. Morocco, a LMIC, has historically had a survival rate for HR neuroblastoma of 10-15% at three years, with almost no survival at five years from diagnosis, due to a combination of limited availability of accurate diagnosis, staging, and risk stratification, as well as lack of some of the necessary treatment modalities and high abandonment rates. The International Society for Pediatric Oncology (SIOP) Pediatric Oncology in Developing Countries (PODC) committee developed adapted risk stratification and treatment guidelines using locally available chemotherapeutic agents in doses that limit toxicity. This approach was implemented at the four cancer treatment centers in Morocco beginning in January of 2012. This study aims to describe HR neuroblastoma patients presenting in Rabat, Morocco, in the last four years; test feasibility of an intensive induction regimen for HR neuroblastoma; and assess response to a novel intensive induction chemotherapy regimen adapted for a LMIC setting. Methods: This treatment protocol was first implemented in January of 2012 with approval of the local ethics board. Chart review was performed on patients with high risk neuroblastoma enrolled on the protocol at Pediatric Hematology and Oncology Center of Rabat between January of 2012 and September of 2015. Data regarding demographics, toxicity, and outcomes was collected and descriptive statistics were performed. Results: 40 patients were diagnosed with high risk neuroblastoma between January of 2012 and September of 2015 in Rabat. There were 14 females (35%) and 26 males (65%) with a median age of 40 months (age range 13m to 11y5m). With regards to diagnostic testing, 100% of patients underwent CT scan, while 47.5% (19/40) of patients underwent MIBG and 47.5% underwent bone scintigraphy. Only 9 patients (22.5%) had MYCN status determined, however MYCN testing increased over time during this protocol, as 53.8% (7/13) of patients diagnosed with HR neuroblastoma in the past year had MYCN testing performed. 82.5% of patients (33/40) completed all five cycles of induction chemotherapy, with 9/40 (22.5%) experiencing delays of 1 or 2 cycles (delay defined as >5 weeks) due to toxicity. Of the 33 patients who completed induction, 60.6% (20 patients) experienced a PR or VGPR, continuing on to local control with surgery or consolidation therapy. Only one patient was lost to follow up due to abandonment. Conclusion: Adapted risk stratification and treatment guidelines for LMICs allow for more accurate diagnosis and systematic treatment. Standardizing a protocol for high risk patients has led to more consistent MYCN evaluation, performed by immunohistochemistry, as well as the introduction of MIBG to the Rabat Children's Hospital. While this is a multi-center study (a known study obstacle in LMICs), this protocol has led to a decrease in the barriers to accurate diagnosis and optimal treatment. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.
Collapse
Affiliation(s)
- Zeena Salman
- Zeena Salman, Memorial Sloan Kettering Cancer Center, New York, NY; Maria El Kababri, Laila Hessissen, and Mohammed Khattab, Children’s Hospital Rabat, Morocco; and Katherine Matthay, University of California San Francisco School of Medicine, CA
| | - Maria El Kababri
- Zeena Salman, Memorial Sloan Kettering Cancer Center, New York, NY; Maria El Kababri, Laila Hessissen, and Mohammed Khattab, Children’s Hospital Rabat, Morocco; and Katherine Matthay, University of California San Francisco School of Medicine, CA
| | - Laila Hessissen
- Zeena Salman, Memorial Sloan Kettering Cancer Center, New York, NY; Maria El Kababri, Laila Hessissen, and Mohammed Khattab, Children’s Hospital Rabat, Morocco; and Katherine Matthay, University of California San Francisco School of Medicine, CA
| | - Mohammed Khattab
- Zeena Salman, Memorial Sloan Kettering Cancer Center, New York, NY; Maria El Kababri, Laila Hessissen, and Mohammed Khattab, Children’s Hospital Rabat, Morocco; and Katherine Matthay, University of California San Francisco School of Medicine, CA
| | - Katherine Matthay
- Zeena Salman, Memorial Sloan Kettering Cancer Center, New York, NY; Maria El Kababri, Laila Hessissen, and Mohammed Khattab, Children’s Hospital Rabat, Morocco; and Katherine Matthay, University of California San Francisco School of Medicine, CA
| |
Collapse
|
34
|
Ziani A, El Kababri M, El Khorassani M, Kili A, Khattab M, Hessissen L. Quels sont les besoins des enfants en oncologie pédiatrique alors qu’ils entrent en phase palliative ? Enquête réalisée au Maroc auprès de leurs parents. PSYCHO-ONCOLOGIE 2015. [DOI: 10.1007/s11839-015-0530-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
35
|
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer 2015; 62:1305-16. [PMID: 25810263 PMCID: PMC5132052 DOI: 10.1002/pbc.25501] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 01/30/2015] [Indexed: 12/11/2022]
Abstract
Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse.
Collapse
Affiliation(s)
- Nehal S. Parikh
- Department of PediatricsDivision of Hematology‐OncologyConnecticut Children's Medical CenterHartfordConnecticut
| | | | | | - Trijn Israels
- VU University Medical CenterAmsterdamthe Netherlands
| | - Mohammed Khattab
- Department of PaediatricsChildren's Hospital of RabatRabatMorocco
| | - Patricia Alcasabas
- University of the Philippines‐Philippine General HospitalManilaPhilippines
| | - Catherine G. Lam
- Department of Oncology and International Outreach ProgramSt. Jude Children's Research HospitalMemphisTennessee
| | | | - Julie R. Park
- Seattle Children's HospitalUniversity of Washington School of Medicine and Fred Hutchinson Cancer Research CenterSeattleWashington
| | - Wendy B. London
- Harvard Medical SchoolBoston Children's Hospital and Dana Farber Cancer InstituteBostonMaryland
| | - Katherine K. Matthay
- Department of PediatricsUCSF School of Medicine and UCSF Benioff Children's HospitalSan FranciscoCalifornia
| |
Collapse
|
36
|
Abd El-Salam M, Somaa H, Khattab M, Abdel Aly A. EVALUATION OF SOME COTTON VARIETIES TO PIERCING SUCKING INSECTS INFESTATION. Journal of Plant Protection and Pathology 2015; 6:9-17. [DOI: 10.21608/jppp.2015.53043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
37
|
Al-Mulla NA, Chandra P, Khattab M, Madanat F, Vossough P, Torfa E, Al-Lamki Z, Zain G, Muwakkit S, Mahmoud S, Al-Jassmi A, Tuncer M, Al-Mukharraq H, Barsaoui S, Arceci RJ, Howard SC, Kulozik AE, Ravindranath Y, Reaman GH, Farranoush M, AlNasser AA. Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA). Pediatr Blood Cancer 2014; 61:1403-10. [PMID: 24648275 DOI: 10.1002/pbc.25031] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 02/13/2014] [Indexed: 11/06/2022]
Abstract
BACKGROUND Little is known about childhood ALL in the Middle East. This study was undertaken by MECCA as initial efforts in collaborative data collection to provide clinical and demographic information on children with ALL in the Middle East. PROCEDURE Clinical and laboratory data for patients with ALL between January 2008 and April 2012 were prospectively collected from institutions in 14 Middle East countries and entered into a custom-built-database during induction phase. All laboratory studies including cytogenetics were done at local institutions. RESULTS The 1,171 voluntarily enrolled patients had a mean age of 6.1 ± 3.9 years and 59.2% were boys. T-ALL represented 14.8% and 84.2% had B-precursor ALL. At diagnosis, 5.6% had CNS disease. The distribution of common genetic abnormalities reflected a similar percentage of hyperdiploidy (25.6%), but a lower percentage of ETV6-RUNX1 translocation (14.7%) compared to large series reported from Western populations. By clinical criteria, 47.1% were low/standard risk, 16.9% were intermediate risk, and 36% were high risk. Most patients received all their care at the same unit (96.9%). Patients had excellent induction response to chemotherapy with an overall complete remission rate of 96%. Induction toxicities were acceptable. CONCLUSIONS This first collaborative study has established a process for prospective data collection and future multinational collaborative research in the Middle East. Despite the limitations of an incomplete population-based study, it provides the first comprehensive baseline data on clinical characteristics, laboratory evaluation, induction outcome, and toxicity. Further work is planned to uncover possible biologic differences of ALL in the region and to improve diagnosis and management.
Collapse
Affiliation(s)
- Naima A Al-Mulla
- Department of Pediatrics, Section of Hematology/Oncology, Doha, Qatar
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Medrare L, Ngeuleu A, Rkain M, Bouaddi I, Znat F, El Kabbaj S, Lakhdar T, Benslama I, Rkain H, Allali F, Khattab M, El Khorassani M, Hajjaj-Hassouni N. AB0903 Is There Any Relationship between the Children Health Assessment Questionnaire (CHAQ) and the European Quality of Life (EUROQOL) in Children Suffering from Chronic Haemophilic Arthropathy?: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Sekkate S, Kairouani M, Hssissen L, El Kabbaj H, Boutayeb S, Mrabti H, Khattab M, Errihani H. Revue de la littérature à propos de 18 cas de lymphome de Burkitt du maxillaire chez l’enfant. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Brahmi SA, Khattab M, Mesbahi OE. Obstructive jaundice secondary to pancreatic head adenocarcinoma in a young teenage boy: a case report. J Med Case Rep 2011; 5:439. [PMID: 21896179 PMCID: PMC3177935 DOI: 10.1186/1752-1947-5-439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2010] [Accepted: 09/06/2011] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Pancreatic adenocarcinoma is extremely rare in childhood. We report a case of metastatic pancreatic adenocarcinoma in a 13-year-old boy, revealed by jaundice. CASE PRESENTATION A 13-year-old Moroccan boy was admitted with obstructive jaundice to the children's Hospital of Rabat, Department of Pediatric Oncology. Laboratory study results showed a high level of total and conjugated bilirubin. Computerized tomography of the abdomen showed a dilatation of the intra-hepatic and extra-hepatic bile ducts with a tissular heterogeneous tumor of the head of the pancreas and five hepatic lesions. Biopsy of a liver lesion was performed, and a histopathological examination of the sample confirmed the diagnosis of metastatic ductal adenocarcinoma of the pancreas. Our patient underwent a palliative biliary derivation. After that, chemotherapy was administered (5-fluorouracil and epirubicin), however no significant response to treatment was noted and our patient died six months after diagnosis. CONCLUSION Malignant pancreatic tumors, especially ductal carcinomas, are exceedingly rare in the pediatric age group and their clinical features and treatment usually go unappreciated by most pediatric oncologists and surgeons.
Collapse
Affiliation(s)
- Sami Aziz Brahmi
- Medical Oncology unit, Hassan II University Hospital, Fez, Morocco.
| | | | | |
Collapse
|
41
|
Otmani N, Alami R, Hessissen L, Mokhtari A, Soulaymani A, Khattab M. Determinants of severe oral mucositis in paediatric cancer patients: a prospective study. Int J Paediatr Dent 2011; 21:210-6. [PMID: 21362073 DOI: 10.1111/j.1365-263x.2011.01113.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To analyse the incidence and the determinants of severe oral mucositis (OM) in young cancer patients treated by standard chemotherapy. METHODS The study was carried out at the Pediatric Hemato-Oncology unit of Children's Hospital of Rabat. Patients under 16 years of age with malignant disease treated by chemotherapy between January 2001 and December 2006 were recorded. RESULTS Consecutive patients (n = 970) with malignant disease were studied. The age ranges from 2 months to 16 years (mean, 6.8 ± 4.1 years). OM occurred in 540 (55.6%) patients, and 17.9% of them encountered severe grades. Mean time to onset of the lesions was 10.5 ± 6.8 (range, 1-22 days) and mean duration was 6.8 ± 3.1 (range, 2-23 days). All chemotherapeutic protocols were associated with OM development (range, 20-100%). Patients with severe OM were more likely to have undifferentiated carcinoma of nasopharyngeal type (RR = 2.6, 95% IC 1.1-6.1), non-Hodgkin lymphoma (RR = 2.1, 95% CI 1.2-2.4) and acute leukaemia (RR = 1.7, 95% CI 1.5-3.6). Methotrexate-based therapies were also associated with the worsening of OM (RR = 1.7, 95% IC 1.2-2.6). CONCLUSION Underlying disease and chemotherapy regimens are the principal risk factors of OM development. This model can help in the identification of patients at risk for adequate preventive and therapeutic measures.
Collapse
Affiliation(s)
- Naïma Otmani
- Pediatric Hemato-Oncology Unit, Children Hospital, Rabat, Morocco.
| | | | | | | | | | | |
Collapse
|
42
|
Lamalmi N, Rouas L, Cherradi N, Malihy A, Khattab M, Alhamany Z. Néphroblastome botryoïde étendu au duodénum. Arch Pediatr 2010; 17:1664-6. [DOI: 10.1016/j.arcped.2010.08.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Revised: 12/28/2009] [Accepted: 08/12/2010] [Indexed: 11/27/2022]
|
43
|
Karkouri M, Zafad S, Khattab M, Benjaafar N, El Kacemi H, Sefiani S, Kettani F, Dey S, Soliman AS. Epidemiologic profile of pediatric brain tumors in Morocco. Childs Nerv Syst 2010; 26:1021-7. [PMID: 20179946 PMCID: PMC4276037 DOI: 10.1007/s00381-010-1097-y] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2009] [Accepted: 01/29/2010] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Brain tumors are the most common solid tumors diagnosed among children below 15 years worldwide. However, little is known about the profile of pediatric brain tumors in Africa. The purpose of this study was to further elaborate the epidemiological profile of pediatric brain tumors in Africa, specifically Morocco. METHODS A retrospective review was conducted of all patients with primary brain tumors in the age group 0-19 years, from 2003 to 2007, from multiple centers in two cities of Rabat and Casablanca, Morocco. Only patients with histopathological confirmation were included (n = 542). Descriptive epidemiologic profiles were created for the patients by age, sex, and histological subtypes of brain tumors. RESULTS Overall medulloblastoma was the most common brain tumor (34.5%), followed by pilocytic astrocytoma (17.3%) and diffuse astrocytoma grade 2 (12.5%). Brain tumors occurred most commonly in 5-9-year age group followed by 10-14-year age group with the former being more common among males and the latter being more common among females. We also found medulloblastoma to be the most common brain tumor in the 0-14-year-olds. CONCLUSIONS In this rare study focused on pediatric brain tumors in Morocco, most of the findings were consistent with past studies from other parts of the world. However, we found medulloblastoma to be the most common pediatric brain tumor followed by astrocytoma.
Collapse
Affiliation(s)
- Mehdi Karkouri
- Department of Pathology, Centre Hospitalier Universitaire Ibn Rochd, 24, rue Jalal Eddine Essayouti, MA20100 Casablanca, Morocco
| | - Sadia Zafad
- Department of Hematology and Pediatric Oncology, Hôpital du 20 Août 1953, Casablanca, Morocco
| | - Mohammed Khattab
- Department of Pediatric Hematology and Oncology, Rabat Children’s Hospital, Rabat, Morocco
| | | | | | - Sana Sefiani
- Department of Pathology, Hôpital des Spécialités, Rabat, Morocco
| | | | - Subhojit Dey
- Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory St., Ann Arbor, MI 48109, USA
| | - Amr S. Soliman
- Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory St., Ann Arbor, MI 48109, USA
| |
Collapse
|
44
|
Agouzal M, Quyou A, Benchekroune K, Khattab M. [Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco]. Rev Med Brux 2010; 31:79-87. [PMID: 20677662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The study aims to give a general idea about the new experience of chelating drugs among beta-thalassemia patients. It is a declarative survey. It was done in the therapy center of Morocco. Statistics were done in the Laboratory of Biological Essays in Kenitra. All economic and pharmacological data were given by Novartis. Sample size was 89. The only treatment available now in the therapy center is deferiprone. 78% of patients attending the service regularly take deferiprone as treatment while 13% of them combine deferiprone and deferoxamine. Most of the patients take treatments regularly. Chelators have reduced mortality. Patients taking deferoxamine experienced injection site reactions. Most of ADR due to deferiprone were digestive. In conclusion, the main problem with chelators in Morocco is lack of accessibility to drugs (except for some patients insured or payant).
Collapse
Affiliation(s)
- M Agouzal
- Université Ibn Tofaïl, Faculté des Sciences, Laboratoire des Essais Biologiques, Kenitra, Maroc.
| | | | | | | |
Collapse
|
45
|
Khattab M, Gilmore G, Sahovic E, Miller S, Rossetti J, Abdulhaq H, Lister J. Viability And Potency Of Hematopoietic Progenitor Cells After Prolonged Cryopreservation At -80 °C. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Lemsaddek W, Picanço I, Seuanes F, Nogueira P, Mahmal L, Benchekroun S, Khattab M, Osório-Almeida L. The β‐Thalassemia Mutation/Haplotype Distribution in the Moroccan Population. Hemoglobin 2009; 28:25-37. [PMID: 15008262 DOI: 10.1081/hem-120028884] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The present study compiles the results of our own research and of a prior study on beta-thalassemia (thal) in Morocco, comprising a total of 187 beta-thalassemic chromosomes. Six major mutations: (beta0) codon 39 (C --> T), (beta+) IVS-I-6 (T --> C), (beta0) frameshift codon (FSC) 6 (-A), (beta0) FSC 8 (-AA), (beta0) IVS-I-1 (G --> A) and (beta+) -29 (A --> G) account for 75.7% of the independent chromosomes studied. A regional predominance was observed (Gharb and West regions) for the (beta+) IVS-I-6 (T --> C) mutation. Despite an observed heterogeneity of molecular anomalies, a direct method of diagnosis of the prevalent mutations is feasible in this population. The distributions of mutations and haplotypes are in conformity with the geographical location of Morocco and the historical links with both the Mediterranean communities that have successively interspersed with the Berbers, the Phoenicians, the Carthaginians, the Romans, the Arabs, the population of the Iberian Peninsula and, to a lesser degree, the Vandals and the Byzantines and permanently, with the Sub-Saharan Africans. In the adult population, the levels of fetal hemoglobin (Hb) in heterozygotes vary from trace quantities to 2.38 g/dL of total Hb. With the exception of the (beta0) codon 39 (C --> T) nonsense mutation, no statistically significant correlation was found, neither between mutation and Hb F levels, nor gender and Hb F levels in heterozygotes. The genetic markers for Hb F increase, located within cis active sites such as the XmnI site at -158 bp of the Ggamma-globin gene and the AT(X)T(Y) repeat region at -540 bp of the beta-globin gene, were assessed. The polymorphism XmnI shows linkage disequilibrium with haplotypes III, IV and IX, as previously observed in the Algerian, Sicilian and Portuguese beta-thal populations. Contrary to what has previously been reported for a population of beta-thal carriers of European descent, this sample does not show a statistically significant correlation between Hb F levels and the presence of the genetic markers XmnI restriction site at -158 bp of the Ggamma-globin gene and AT(X)T(Y) alleles at 5' of the beta-globin gene.
Collapse
Affiliation(s)
- Wafaâ Lemsaddek
- Laboratório de Genética Molecular, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatr Hematol Oncol 2009; 26:216-31. [PMID: 19437324 DOI: 10.1080/07357900902897557] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
CD10 and CD34 expression in 86 Moroccan children with acute lymphoblastic leukemias (ALL) and the relevance to prognosis, diagnosis, and outcome during a 5-year follow-up were examined. At diagnosis, 57% of patients had CD10(+) blasts, while 35% had CD34(+) blasts. The CD10(+) blast frequency was much higher (80%) in B-ALL than in T-ALL (20%). The frequency of CD34(+) blasts was higher in B-ALL (48%) compared to T-ALL (16%). The 5-year survival curves showed that children with CD10(+) B-ALL had a significantly longer survival rate than those with CD10(-), as observed for T-ALL. The survival rate of B-ALL expressing CD34 was higher than that of CD34(-). Thus, CD34 and CD10 expression may have prognostic value and is associated with a better clinical outcome.
Collapse
Affiliation(s)
- Nadia Dakka
- Laboratoire de Biochimie et Immunologie, Faculté des Sciences, Université Mohammed V, Rabat, Morocco.
| | | | | | | | | | | |
Collapse
|
48
|
Almaslmani M, Derbala M, Albozom I, Khattab M, Chacko K, Alani A. Bronchiolitis obliterans organizing pneumonia associated withPneumocystis jiroveciinfection in orthotopic liver transplantation. Transpl Infect Dis 2008; 10:339-42. [DOI: 10.1111/j.1399-3062.2008.00300.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Otmani N, Alami R, Soulaymani A, El Mokhtari A, Khattab M. Sex, age and ABO blood groups in chemotherapy-induced oropharyngeal mucositis. Minerva Stomatol 2008; 57:505-509. [PMID: 19078892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
AIM The contribution of host genetic factors in oropharyngeal mucositis is not fully understood. Therefore, we conducted this study to determine possible associations of age, sex, underlying disease, type of chemotherapy and ABO blood group antigens with the risk of chemotherapy-induced oropharyngeal mucositis. METHODS A total of 641 patients (395 boys and 246 girls; mean age 6.82+/-4.08 years) treated by standard chemotherapy for different type of malignancies were enrolled in the study. Mucositis was scored using the WHO scale. RESULTS Oropharyngeal mucositis was found in 65.4% of our population. Patients with hematological malignancies (RR=1.87; 95% CI 1.33-2.67; P<0.0001) and under antimetabolities drugs (RR=1.88; 95% CI 1.33-2.63; P<0.0001) were associated with increased risk of oropharyngeal mucositis. Also, patients with blood group O were at higher risk (RR=2.86; 95% CI 2.03-4.02; P<0.0001) compared to patients with blood type A (RR= 0.47; 95% CI 0.33-0.66; P<0.0001) and blood type B (RR=0.59; 95% CI 0.38-0.91; P= 0.01). No relationship was found between oropharyngeal mucositis and age or sex. CONCLUSIONS To our knowledge this is the first report demonstrating an association between ABO blood group and oropharyngeal mucositis. Further investigations are needed for a better understanding of this relationship.
Collapse
Affiliation(s)
- N Otmani
- Unit of Pediatric Hemato-Oncology, Children Hospital, Rabat, Morocco.
| | | | | | | | | |
Collapse
|
50
|
Harif M, Barsaoui S, Benchekroun S, Bouhas R, Doumbé P, Khattab M, Ladjaj Y, Moreira C, Msefer-Alaoui F, Patte C, Rakotonirina G, Raphael M, Raquin MA, Lemerle J. Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 2008; 50:1138-42. [PMID: 18213709 DOI: 10.1002/pbc.21452] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The French African Paediatric Oncology Group (GFAOP) was set up in October 2000 to improve the quality of care of children with cancer in Africa. Eight pediatric oncology units from Algeria, Cameroon, Madagascar, Morocco, Tunisia, and Senegal have been involved. METHODS Patients less than 18 years with cytology or histology proven B-cell non-Hodgkin lymphoma were included. Two LMB89 modified regimens were proposed (MAT and GFA). RESULTS From April 2001 to April 2004, 343 cases were registered. Thirty seven patients were excluded. Thirteen patients were stage I, 26 stage II, 209 stage III and 50 stage IV including 8 L3 acute lymphoblastic leukemia (ALL3) cases. Three year OS of the whole population of patients is 61%. In GFA group 36 months OS is 63.6% in stages I/II, 51.6% in stage III and 35.8% in stage IV. In MAT group, the OS is 84.4% in stages I/II, 76.2% in stage III and 55.6% in stage IV. Seventy one patients died during treatment, 32 at pre-induction phase, 27 at induction and 12 at consolidation. Treatment related mortality decreased during the 3-year inclusion period (first year: 25.7%, second year: 19.1%, third year: 11.6%). The improvement of supportive care translated into an increase of the overall survival rates from 54% in the first year to 73% in the third year. CONCLUSION These data demonstrate the feasibility of prospective multicentric studies in Africa. An improvement of quality of care has been noticed during the 3 first years.
Collapse
Affiliation(s)
- Mhamed Harif
- Service d'Hématologie et Oncologie Pédiatrique, Hôpital 20 Août 1953, Casablanca, Morocco.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|